This is a repository copy of *Natural killer cell recognition of glioblastoma*.

White Rose Research Online URL for this paper:  
http://eprints.whiterose.ac.uk/85248/

Version: Accepted Version

**Proceedings Paper:**  

https://doi.org/10.1111/imm.12406

---

**Reuse**  
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

**Takedown**  
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Glioblastoma multiforme (GBM) is the most common form of primary brain cancer. GBM is infiltrated by immune cells but, as with other cancers, immune evasion pathways minimise productive anti-tumour immunity. We have investigated the interaction of human natural killer (NK) cells with GBM using both established tumour cell lines and patient-derived samples. A high-throughput, multiplex flow cytometry-based screen of tumour cells revealed the expression of a number of cell surface molecules that regulate NK cell activation. Furthermore, GBM cells were susceptible to NK cell lysis in vitro. This screen identified potential mechanisms by which GBM might evade immune surveillance in vivo. Analysis of the cell surface phenotype of brain cancer infiltrating immune cells will be used to test the hypothesis that the tumour microenvironment exerts localised immune evasion mechanisms that serve to dampen anti-tumour immunity. Targeting these pathways and restoring functional immune surveillance provides a potential route for future immunotherapy of this disease.